PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 49 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Teacher Reads To Students One Day After Having Brain Surgery October 26, 2021 No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... September 9, 2021 Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief... June 8, 2021 The (un)usual suspects – how early detection research embraces interdisciplinary science August 20, 2021 Load more HOT NEWS FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era Making Important Decisions During Cancer: A Survivor’s Story
